Vincent Tam to beta-Lactamase Inhibitors
This is a "connection" page, showing publications Vincent Tam has written about beta-Lactamase Inhibitors.
Connection Strength
3.270
-
Optimizing pharmacokinetics/pharmacodynamics of ?-lactam/?-lactamase inhibitor combinations against high inocula of ESBL-producing bacteria. J Antimicrob Chemother. 2021 01 01; 76(1):179-183.
Score: 0.732
-
What the Clinical Microbiologist Should Know About Pharmacokinetics/Pharmacodynamics in the Era of Emerging Multidrug Resistance: Focusing on ?-Lactam/?-Lactamase Inhibitor Combinations. Clin Lab Med. 2019 09; 39(3):473-485.
Score: 0.660
-
Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-?-Lactamase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2019 02; 63(2).
Score: 0.640
-
In vitro activity of MK-7655, a novel ?-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother. 2012 Jul; 56(7):3753-7.
Score: 0.401
-
Novel modeling framework to guide design of optimal dosing strategies for ?-lactamase inhibitors. Antimicrob Agents Chemother. 2012 May; 56(5):2237-40.
Score: 0.395
-
Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2022 10 28; 77(11):3130-3137.
Score: 0.208
-
New ?-Lactam-?-Lactamase Inhibitor Combinations. Clin Microbiol Rev. 2020 12 16; 34(1).
Score: 0.181
-
A novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE)?bloodstream infections. Int J Antimicrob Agents. 2023 Apr; 61(4):106760.
Score: 0.053